Marisa Wexler, MS,  senior science writer—

Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.

Articles by Marisa Wexler

COVID-19 Treatments Opening to High-risk Patients in UK via NHS

People in the U.K. at highest risk of becoming seriously ill from COVID-19 — including those with cystic fibrosis (CF) — starting on Dec. 16 will have access to medications that can lessen the risk of severe disease through the country’s National Health Service (NHS). Two medications will be available:…

Self-compassion Tied to Better Quality of Life in Adults With CF

People with cystic fibrosis (CF) who score highly on measures of self-compassion tend also to report higher quality of life, a study found. “The current findings suggest that psychological interventions which increase self-compassion could be beneficial for enhancing better mental health and quality of life for adults with CF,”…

CHMP Favors Kaftrio to Treat Children in EU Starting at Age 6

A branch of the European Medicines Agency (EMA) has recommended expanding Kaftrio (ivacaftor/tezacaftor/elexacaftor), in combination with Kalydeco (ivacaftor), to include children with cystic fibrosis (CF) as young as age 6 who have at least one F508del mutation. The recommendation, from the EMA’s Committee for Medicinal Products for Human Use (CHMP),…

Your CF Community


Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.